Abstract:Background: Presently, viral vector used in gene therapy has immunogenicity to the body and has a potential to infect, so it has limitation to be used in clinic. Onjective: To construct the non-pathogenic recombinant adeno-associated virus (AAV) simultaneously carrying human vascular endothelial growth factor 165 (hVEGF 165) gene and green fluorescent protein (GFP) label, and assess its biological activity and function by infecting rabbit bone marrow mesenchymal stem cells (BMSCs) in vitro. Design, Time and Setting: An open experiment was performed at the Laboratory of Virus of Shanxi Provincial Center for Disease Control and Prevention between March and November 2007. Materials: BMSCs were harvested from mature New Zealand rabbits after primary culture by the experimenter. Human umbilical vein endothelial cells (HUVECs) were harvested from infant umbilical cores of healthy parturients. Informed consents were obtained from parturients. Methods: Plasmid pAAV-hVEGF 165-IRES-hrGFP was constructed by hVEGF 165 segments amplified from plasmid pUC18-hVEGF165 carrying hVEGF 165 gene. The recombinant expression plasmid pAAV-hVEGF165-IRES-hrGFP was co-transfected into AAV-293 cells with pAAV-Helper and pAAV-RC for recombinant AAV replication and package through homologous recombination. In vitro cultured rabbit BMSCs were infected with this recombinant virus. Main Outcome Measure: The efficiency of AAV packaging was monitored under a fluorescent microscope and the virus titer was measured through infecting AAV-HT1080, and the recombinant virus was verified by polymerase chain reaction (PCR) of the exogenous interest gene. Through infecting rabbit bone marrow mesenchymal stem cells in vitro, the infection efficiency was detected. The expression of VEGF 165 in BMSCs was detected by enzyme linked immunosorbent assay (ELISA), and its biological activity was assessed by angiopoiesis experiment of HUVECs in vitro. Results: The hVEGF 165 gene was successfully amplified and recombinant pAAV-hVEGF 165-IRES-GFP was verified by double digestion. The system provided a high packing ratio of more than 95% and the purified recombinant virus had a high titer of 5.5 × 10 11 vp/mL. The recombinant virus was confirmed by exogenous human VEGF 165 gene PCR. The rAAV-VEGF 165-GFP could infect rabbit BMSCs at a ratio of 40%. With rAAV-VEGF165-GFP infection, the expression of VEGF 165 in the conditional medium was detected by ELISA at a concentration of (85.58±5.37) μ g/L 72 hours after infection. HUVECs became extended, deformed, pullulation, cross-linking and showing tube-shape affected by VEGF protein. Conclusion: The non-pathogenic rAAV-hVEGF 165-GFP simultaneously carrying hVEGF 165 and GFP label is successfully constructed, with the ability of infecting rabbit BMSCs to efficiently express hVEGF 165, and hVEGF 165 expressed in BMSCs has a satisfying biological activity of stimulation of HUVECs proliferation.

Construction of Recombinant Adenovirus Expressing the Small Interfering RNA of Vascular Endothelial Growth Factor-C

Construction and Identification of Lentiviral Vector-mediated RNA Interference of Epidermal Growth Factor Receptor

Construction of Recombinant Adenovirus Coding for Vascular Endothelial Growth Factor Gene

The Construction and Characterization of a Novel Adenovirus Vector of Artificial Microrna Targeting EGFR.

Study on Inhibitation of the Tube Formation by RNA Introduced by Adenovirus by its Interference With and Decrease of VEGF Transcription

Cloning and Construction of Adenovirus Expressing Human Angiopoietin-1 or Vascular Endothelial Growth Factor

Construction and Identification of Recombinant Adeno- Associated Virus Vector Co-Expressing Human Vascular Endothelial Growth Factor and Green Fluorescent Protein

Construction of Adenovirus Vector with Human Interleukin 10 and Its Expression in Vascular Smooth Muscle Cells

Establishment of A Recombinant Adeno-Associated Virus Expressing Hvegf(165)

Construction of recombinant adenovirus coding for the cDNA of human acidic fibroblast growth factor and the research of its gene transfection efficiency and safety

Construction and Expression of a Lentivirus Expression Vector Carrying the VEGF165-EGFP Fusion Gene in Breast Cancer MCF-7 Cells.

Construction of Recombinant Adenovirus for the Angiogenic Inhibitor,Vasostatin,and Its Expression in Vitro

Gene cloning of secreted VEGF receptor flt-1 (I similar to IV extracellular domain) and the corresponding recombinant adenovirus construction and expression

[Preparation and characterization of Ad-ERα-36-Fc-GFP].

Construction of A Lentiviral Vector Simultaneously Expressing Active IGF1, EGF and FGF2

Recombinant Human Vascular Endothelial Growth Factor-C and Its Expression in vitro

Construction of recombinant adeno-associated virus carrying human vascular endothelial growth factor 165 and in vitro infection of bone marrow mesenchymal stem cells

Construction of Psuper-H1 RNAi System Inhibiting the Expression of VEGF

Expression of vascular endothelial growth factor in endothelial progenitor cells following its expression vector construction

Construction of a vascular endothelial growth factor and sodium iodide symporter gene co-expressing eukaryotic vector

[Construction of Lentivirus Vector Carrying HGF and Exploration of Transfection Condition of Rat Adipocyte-derived Mesenchymal Stem Cells].